acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor
Findings
No curated finding names acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor yet. Everything below is reference data from Mondo, HPO and GenCC, not evidence about what affects it.
Definition
Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor represent a subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposid, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement.
Definition from the Mondo Disease Ontology (MONDO:0015165), read 2026-09-29. CC BY 4.0.
Where it sits
Other names
1 name
Resolves to: acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor
- Also called
- AML and myelodysplastic syndromes related to topoisomerase type 2 inhibitor